vs

Side-by-side financial comparison of SolarMax Technology, Inc. (SMXT) and Valneva SE (VALN). Click either name above to swap in a different company.

SolarMax Technology, Inc. is the larger business by last-quarter revenue ($46.6M vs $36.2M, roughly 1.3× Valneva SE). SolarMax Technology, Inc. runs the higher net margin — -1.9% vs -54.1%, a 52.2% gap on every dollar of revenue.

SolarMax Technology, Inc. develops, manufactures and sells high-efficiency solar PV modules and clean energy systems. It serves residential, commercial and industrial clients in North America and key Asia-Pacific markets, offering installation and after-sales support to boost low-carbon energy use.

Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.

SMXT vs VALN — Head-to-Head

Bigger by revenue
SMXT
SMXT
1.3× larger
SMXT
$46.6M
$36.2M
VALN
Higher net margin
SMXT
SMXT
52.2% more per $
SMXT
-1.9%
-54.1%
VALN

Income Statement — Q4 FY2025 vs Q1 FY2023

Metric
SMXT
SMXT
VALN
VALN
Revenue
$46.6M
$36.2M
Net Profit
$-872.2K
$-19.6M
Gross Margin
2.7%
38.9%
Operating Margin
-2.7%
-49.5%
Net Margin
-1.9%
-54.1%
Revenue YoY
623.5%
Net Profit YoY
77.7%
EPS (diluted)
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SMXT
SMXT
VALN
VALN
Q4 25
$46.6M
Q3 25
$30.6M
Q2 25
$6.9M
Q1 25
$6.9M
Q4 24
$6.4M
Q3 24
$6.3M
Q1 23
$36.2M
Q2 22
$93.2M
Net Profit
SMXT
SMXT
VALN
VALN
Q4 25
$-872.2K
Q3 25
$-2.3M
Q2 25
$-1.9M
Q1 25
$-1.3M
Q4 24
$-3.9M
Q3 24
$-9.6M
Q1 23
$-19.6M
Q2 22
Gross Margin
SMXT
SMXT
VALN
VALN
Q4 25
2.7%
Q3 25
3.1%
Q2 25
8.8%
Q1 25
20.5%
Q4 24
14.5%
Q3 24
19.9%
Q1 23
38.9%
Q2 22
Operating Margin
SMXT
SMXT
VALN
VALN
Q4 25
-2.7%
Q3 25
-6.9%
Q2 25
-25.7%
Q1 25
-16.7%
Q4 24
-27.9%
Q3 24
-158.4%
Q1 23
-49.5%
Q2 22
-161.3%
Net Margin
SMXT
SMXT
VALN
VALN
Q4 25
-1.9%
Q3 25
-7.4%
Q2 25
-27.6%
Q1 25
-18.7%
Q4 24
-60.6%
Q3 24
-152.0%
Q1 23
-54.1%
Q2 22
EPS (diluted)
SMXT
SMXT
VALN
VALN
Q4 25
$-0.02
Q3 25
$-0.04
Q2 25
$-0.04
Q1 25
$-0.03
Q4 24
$-0.07
Q3 24
$-0.21
Q1 23
Q2 22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SMXT
SMXT
VALN
VALN
Cash + ST InvestmentsLiquidity on hand
$8.0M
$274.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-12.2M
$221.2M
Total Assets
$91.3M
$637.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SMXT
SMXT
VALN
VALN
Q4 25
$8.0M
Q3 25
$5.7M
Q2 25
$1.9M
Q1 25
$6.8M
Q4 24
$7.1M
Q3 24
$8.6M
Q1 23
$274.8M
Q2 22
$363.1M
Stockholders' Equity
SMXT
SMXT
VALN
VALN
Q4 25
$-12.2M
Q3 25
$-11.8M
Q2 25
$-15.1M
Q1 25
$-15.9M
Q4 24
$-15.1M
Q3 24
$-10.9M
Q1 23
$221.2M
Q2 22
$100.7M
Total Assets
SMXT
SMXT
VALN
VALN
Q4 25
$91.3M
Q3 25
$58.7M
Q2 25
$38.2M
Q1 25
$38.6M
Q4 24
$38.6M
Q3 24
$43.0M
Q1 23
$637.2M
Q2 22
$783.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SMXT
SMXT
VALN
VALN
Operating Cash FlowLast quarter
$-2.5M
$-26.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SMXT
SMXT
VALN
VALN
Q4 25
$-2.5M
Q3 25
$3.4M
Q2 25
$220.7K
Q1 25
$-601.1K
Q4 24
$-1.3M
Q3 24
$203.6K
Q1 23
$-26.3M
Q2 22
Capex Intensity
SMXT
SMXT
VALN
VALN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.0%
Q1 23
Q2 22

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SMXT
SMXT

Yabucoa$35.9M77%
Other$10.7M23%

VALN
VALN

Segment breakdown not available.

Related Comparisons